Newly Emerged ROS1 Rearrangement in a Patient with Lung Adenocarcinoma Following Resistance to Immune Checkpoint Inhibitors: a Case Report

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Dec 26

PMID 39723367

Authors

Jian Wang

Bingyue Liu

Qinhong Zheng

Ruoshui Xiao

Jianxin Chen

Affiliations

Soon will be listed here.

Abstract

Background: ROS1, a member of the sevenless subfamily of tyrosine kinase insulin receptors, promotes tumor cell survival, proliferation, and metastasis by activating the JAK/STAT, PI3K/AKT, and MAPK/ERK pathways. It only accounts for about 2% of total NSCLC cases. No cases of acquired ROS-1 rearrangement have been reported worldwide.

Case Presentation: We reported a case of lung adenocarcinoma without driver alteration that developed resistance to pembrolizumab and newly emerged CD74-ROS1 fusion, and achieved a partial response after entrectinib treatment.

Conclusions: We hypothesize that the newly emerged ROS1 rearrangement occurs as the subset of cells harboring ROS1 gradually becomes the predominant pathological type of adenocarcinoma following pembrolizumab treatment. We propose that new therapeutic targets may emerge for this patient population following long-term immunotherapy. Thus, we advocate for regular monitoring of tumor genetic status, which could yield unexpected benefits.

References

Wei Z, Zhou Y, Pu X, Yan X . [Potential Value of Neoadjuvant Immunochemotherapy in Patients  with Driver Gene-positive Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2024; 27(9):674-684. PMC: 11534581. DOI: 10.3779/j.issn.1009-3419.2024.101.24. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Feldt S, Bestvina C . The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications. Cancers (Basel). 2023; 15(11). PMC: 10251884. DOI: 10.3390/cancers15112998. View

Desai A, Peters S . Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev. 2023; 116:102545. DOI: 10.1016/j.ctrv.2023.102545. View

Tang S, Qin C, Hu H, Liu T, He Y, Guo H . Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells. 2022; 11(3). PMC: 8834198. DOI: 10.3390/cells11030320. View

Singh N, Temin S, Baker Jr S, Blanchard E, Brahmer J, Celano P . Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. J Clin Oncol. 2022; 40(28):3323-3343. DOI: 10.1200/JCO.22.00825. View

Nooreldeen R, Bach H . Current and Future Development in Lung Cancer Diagnosis. Int J Mol Sci. 2021; 22(16). PMC: 8395394. DOI: 10.3390/ijms22168661. View

Ettinger D, Wood D, Aggarwal C, Aisner D, Akerley W, Bauman J . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019; 17(12):1464-1472. DOI: 10.6004/jnccn.2019.0059. View

Mamdani H, Matosevic S, Khalid A, Durm G, Jalal S . Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol. 2022; 13:823618. PMC: 8864096. DOI: 10.3389/fimmu.2022.823618. View

10.

Roskoski Jr R . ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol Res. 2017; 121:202-212. DOI: 10.1016/j.phrs.2017.04.022. View

11.

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S . RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3):378-81. DOI: 10.1038/nm.2658. View

12.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

13.

Araghi M, Mannani R, Maleki A, Hamidi A, Rostami S, Safa S . Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023; 23(1):162. PMC: 10416536. DOI: 10.1186/s12935-023-02990-y. View

14.

Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M . Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020; 8(2). PMC: 7555111. DOI: 10.1136/jitc-2020-001001. View

15.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

16.

MacManus M, Hegi-Johnson F . Overcoming immunotherapy resistance in NSCLC. Lancet Oncol. 2022; 23(2):191-193. DOI: 10.1016/S1470-2045(21)00711-7. View